These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15535440)

  • 1. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer.
    Oh WK
    J Urol; 2004 Nov; 172(5 Pt 2):S34-7; discussion S37. PubMed ID: 15535440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
    Oh WK
    J Urol; 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. PubMed ID: 14610407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.
    Oh WK
    Urol Oncol; 2003; 21(3):229-34. PubMed ID: 12810211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant therapy for high-risk localized prostate cancer.
    Yu EY; Oh WK
    Curr Oncol Rep; 2003 May; 5(3):250-7. PubMed ID: 12667424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for localized, high-risk prostate cancer.
    Narayan S; Smith DC; Sandler HM
    Semin Radiat Oncol; 2003 Apr; 13(2):152-7. PubMed ID: 12728444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.
    Pisansky TM
    Urology; 2003 Dec; 62 Suppl 1():36-45. PubMed ID: 14747040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer.
    Nakabayashi M; Oh WK
    Curr Treat Options Oncol; 2004 Oct; 5(5):349-55. PubMed ID: 15341673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising PSA in nonmetastatic prostate cancer.
    Moul JW; Bañez LL; Freedland SJ
    Oncology (Williston Park); 2007 Nov; 21(12):1436-45; discussion 1449, 1452, 1454. PubMed ID: 18077992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.
    Spratt DE; Dess RT; Zumsteg ZS; Lin DW; Tran PT; Morgan TM; Antonarakis ES; Nguyen PL; Ryan CJ; Sandler HM; Cooperberg MR; Posadas E; Feng FY
    Eur Urol; 2018 Feb; 73(2):156-165. PubMed ID: 28716370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
    Lam ET; Glodé LM
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
    Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant and neoadjuvant therapy in prostate cancer.
    Chay C; Smith DC
    Semin Oncol; 2001 Feb; 28(1):3-12. PubMed ID: 11254863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: emerging concepts. Part II.
    Garnick MB; Fair WR
    Ann Intern Med; 1996 Aug; 125(3):205-12. PubMed ID: 8686979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management strategies for locally advanced prostate cancer.
    Jani AB
    Drugs Aging; 2006; 23(2):119-29. PubMed ID: 16536635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
    Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
    Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.